| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 755,859 | 709,171 | 689,892 | 652,800 |
| Accounts receivable, net | 130,834 | 126,477 | 106,409 | 65,863 |
| Inventory | 34,930 | 37,166 | 28,029 | 18,650 |
| Prepaid expenses and other current assets | 18,767 | 21,216 | 28,123 | 21,426 |
| Total current assets | 940,390 | 894,030 | 852,453 | 758,739 |
| Operating lease right-of-use asset, net | 1,858 | 1,935 | 2,010 | 2,084 |
| Property and equipment, net | 994 | 1,037 | 1,077 | 1,149 |
| Gross carrying value | 240,212 | 240,212 | 227,712 | NaN |
| Accumulated amortization | 118,241 | 108,538 | 99,073 | NaN |
| License and acquired intangibles, net | 121,971 | 131,674 | 128,639 | 137,983 |
| Deferred tax assets, net | 55,111 | 52,767 | 48,256 | 50,704 |
| Investment in equity securities | 27,286 | 22,536 | 19,167 | 21,256 |
| Total assets | 1,147,610 | 1,103,979 | 1,051,602 | 971,915 |
| Accounts payable | 7,151 | 11,202 | 9,096 | 5,528 |
| Accrued expenses and other liabilities | 125,247 | 135,950 | 119,639 | 107,479 |
| Total current liabilities | 132,398 | 147,152 | 128,735 | 113,007 |
| Operating lease liability, net of current portion | 2,235 | 2,350 | 2,461 | 2,572 |
| Other non-current liabilities | 280 | 209 | 161 | 309 |
| Total liabilities | 134,913 | 149,711 | 131,357 | 115,888 |
| Common stock, 0.001 par value, 200,000,000 shares authorized 122,181,308 shares and 122,513,621 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 122 | 123 | 123 | 122 |
| Additional paid-in capital | 489,218 | 479,957 | 473,333 | 461,868 |
| Retained earnings | 523,349 | 474,188 | 446,789 | 394,006 |
| Accumulated other comprehensive income (loss) (note 4) | 8 | 0 | 0 | 31 |
| Total stockholders' equity | 1,012,697 | 954,268 | 920,245 | 856,027 |
| Total liabilities and stockholders' equity | 1,147,610 | 1,103,979 | 1,051,602 | 971,915 |
CATALYST PHARMACEUTICALS, INC. (CPRX)
CATALYST PHARMACEUTICALS, INC. (CPRX)